FDAsafety guidance66% confidence
FDA AP — IDVYNSO (ORIG)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Merck; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application NDA216964. Sponsor: MSD. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: DORAVIRINE, ISLATRAVIR.
Supporting Context
- Therapeutic area
- Infectious Disease · HIV
- Sub-indication
- General
Related signal: FDA Approves Merck’s IDVYNSO for Virologically Suppressed HIV-1 Patients